| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/19/2004 | WO2003048193A3 GIPs, A FAMILY OF POLYPEPTIDES WITH TRANSCRIPTION FACTOR ACTIVITY THAT INTERACT WITH GOODPASTURE ANTIGEN BINDING PROTEIN |
| 02/19/2004 | WO2003045974A3 Methods and compositions for derepression of iap-inhibited caspase |
| 02/19/2004 | WO2003043576A3 Flowable osteogenic and chondrogenic compositions |
| 02/19/2004 | WO2003040167A3 Peptides which deliver antisense oligonucleotides and downregulate protein expression in cells |
| 02/19/2004 | WO2003037265A9 Method of treating viral infections |
| 02/19/2004 | WO2003032925A3 Glycosulfopeptide inhibitors and methods of use thereof |
| 02/19/2004 | WO2003032907A3 High-concentration protein formulations and method of manufacture |
| 02/19/2004 | WO2003031587A3 Use of stat-6 inhibitors as therapeutic agents |
| 02/19/2004 | WO2003025014A3 Use of peptides comprising post-translational modifications in the treatment of autoimmune pathologies |
| 02/19/2004 | WO2003020212A3 Treatment for central nervous system disorders |
| 02/19/2004 | WO2003012049A3 Methods and composition concerning herpes virus us3 and bad-involved apoptosis |
| 02/19/2004 | WO2003010291A3 Treatment of immune disorders and b cell disorders |
| 02/19/2004 | WO2003008537A9 Epitope sequences |
| 02/19/2004 | WO2003004622A3 Human secreted proteins |
| 02/19/2004 | WO2003000719A8 Multiple antigenic peptide displaying multiple copies of an epitope of plaque-forming polypeptide and methods of using same |
| 02/19/2004 | WO2003000113A9 Compositions and methods for the diagnosis and treatment of tumor |
| 02/19/2004 | WO2002099085A3 Human secreted proteins |
| 02/19/2004 | WO2002091989A3 Antiviral therapies using polyamine or polyamine analog-amino acid conjugates |
| 02/19/2004 | WO2002090514A8 Epidermal growth factor receptorantisense oligonucleotides |
| 02/19/2004 | WO2002088184A9 A molecular marker |
| 02/19/2004 | WO2002086101A3 Core-glycosylated hcv envelope proteins |
| 02/19/2004 | WO2002086100A3 Expression of core-glycosylated hcv envelope proteins in yeast |
| 02/19/2004 | WO2002083866A3 Repeat sequences of the ca125 gene and their use for diagnostic and therapeutic interventions |
| 02/19/2004 | WO2002078736A3 Antiallergic pharmaceutical composition |
| 02/19/2004 | WO2002076380A3 Cytotoxic factors for modulating cell death |
| 02/19/2004 | WO2002070023A3 Compositions comprising bone marrow cells together with demineralized and/or mineralized bone matrix and uses thereof in the induction of bone and cartilage formation |
| 02/19/2004 | WO2002069884A3 A sunburn treatment and sunburn prevention method |
| 02/19/2004 | WO2002066498A3 Peptide inhibiting platelet derived growth factor (pdgf-bb) and fibroblast growth factor (bfgf) activity |
| 02/19/2004 | WO2002065985A3 Methods of treating diabetes mellitus |
| 02/19/2004 | WO2002064160A3 Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof |
| 02/19/2004 | WO2002061086A3 Human leucine-rich repeat containing protein expressed predominately in small intestine, hlrrsi1 |
| 02/19/2004 | WO2002057566A3 Method for identifying compounds modulating sister chromatid separation |
| 02/19/2004 | WO2002048346A3 Transgenic mice containing bsmap gene disruptions |
| 02/19/2004 | WO2002048337A3 Secreted human proteins |
| 02/19/2004 | WO2002048326A3 Human caplain proteins and polynucleotides coding therefor |
| 02/19/2004 | WO2002048184A8 Glycoprotein peptide of the human herpesvirus-7 for use in particular in an elisa serologic test |
| 02/19/2004 | WO2002046477A3 Endogenous retroviruses up-regulated in prostate cancer |
| 02/19/2004 | WO2002038738A3 Chimeric molecules to modulate gene expression |
| 02/19/2004 | WO2002024214A3 Use of glp -2 in combination with another therapeutic agent in bone-related and nutrition-related disorders |
| 02/19/2004 | WO2001040438A3 Methods and compositions for regulating lymphocyte activity |
| 02/19/2004 | US20040034882 Transgenic rodent with mutation in one allele of the corticotropin releasing factor receptor 2 protein for use as animal model in treating and diagnosing anxiety, depression, obesity and diabetes |
| 02/19/2004 | US20040034878 Using transgenic hypercellular nonhuman organisms as cell proliferating gene therapeutic tools |
| 02/19/2004 | US20040034357 Controlled release implantable devices |
| 02/19/2004 | US20040034229 3,4-Di-substituted maleimide compounds as CXC chemokine receptor antagonists |
| 02/19/2004 | US20040034206 Administering therapeutically effective amount of ribavirin, (S)-N-3-(3-(3-methoxy-4-oxazol-5-yl-phenyl)ureido)benzylcarbam ic acid tetrahydrofuran-3-yl-ester, and pegylated interferon-alpha-2b |
| 02/19/2004 | US20040034202 Ketone spirocyclopropaneindene compounds; antineoplastic agents to inhibit tumor cell growth in vitro or in vivo; particularly effective against solid tumors and multi-drug resistant tumors |
| 02/19/2004 | US20040034201 Enhanced affinity hyaluronan binding peptides |
| 02/19/2004 | US20040034200 Comprises plant oil protein derived from gluten like micellar mass (PMM) for use in animal feeds, pet foods and cosmetics |
| 02/19/2004 | US20040034198 Mutant p53 (delta126-132) protein and uses thereof |
| 02/19/2004 | US20040034196 Comprises nucleotide sequences coding polypeptide for prevention, diagnosis and treatment of neurodegenerative, behavioral, inflammatory and tumor disorders |
| 02/19/2004 | US20040034193 Biosynthetic oncolytic molecules and uses therefor |
| 02/19/2004 | US20040034192 Human proteins having hyprophobic domains and dnas encoding these proteins |
| 02/19/2004 | US20040034095 Low toxicity; side effect reduction |
| 02/19/2004 | US20040034043 Positively-charged peptide nucleic acid analogs with improved properties |
| 02/19/2004 | US20040034001 Administering to the female patient undergoing hormone replacement therapy, an effective amounts of drospirenone (DRSP) and at least one estrogen to reduce the blood pressure |
| 02/19/2004 | US20040033993 Treatment of cardiovascular and related pathologies |
| 02/19/2004 | US20040033992 Treatment of cardiovascular and related pathologies |
| 02/19/2004 | US20040033991 Treating of cardiovascular and related pathologies |
| 02/19/2004 | US20040033990 Administering mixtures of heterocyclic imines, calcium channel blockers, adrenergic blocking agents, anticoagulants, diuretics and angiotensin converting enzyme inhibitors, for prophylaxis of heart diseases such as arrhythmias or necrosis |
| 02/19/2004 | US20040033989 Treatment of cardiovascular and related pathologies |
| 02/19/2004 | US20040033980 Method of down-regulating gene expression |
| 02/19/2004 | US20040033979 Antisense modulation of Fas mediated signaling |
| 02/19/2004 | US20040033976 Antisense modulation of mekk3 expression |
| 02/19/2004 | US20040033971 Polypeptides and nucleic acids encoding same |
| 02/19/2004 | US20040033958 Such as (N-((R,S)-2-(2-(N-methyl)pyrrolidinyl)ethyl)glycyl)-(N-(4 -methoxyphenethyl)glycyl)-N-(3-methylbutyl)glycinamide; for treatment of pain |
| 02/19/2004 | US20040033955 Treatment of ophthalmic infections using antimicrobial peptides |
| 02/19/2004 | US20040033954 Therapeutic method for combined use of modified CNTF and thiadolidinedione |
| 02/19/2004 | US20040033952 Modified mature insulin variants and composition containing same |
| 02/19/2004 | US20040033951 Modified mature insulin variants and composition containing same |
| 02/19/2004 | US20040033950 Administering parathyroid hormone; crystal proteins; for treatment of osteoporosis |
| 02/19/2004 | US20040033949 Use of VEGF for treating bone defects |
| 02/19/2004 | US20040033947 Method for treating hemophilia b |
| 02/19/2004 | US20040033946 Cell damage inhibitor |
| 02/19/2004 | US20040033945 Pharmaceutical compositions for treating asthenia or anaemia or for making a food supplement |
| 02/19/2004 | US20040033944 Administering to patient in need thereof an effective amount of an angiogenic growth factor, or active fragment thereof such as endothelial growth factor or fibroblast growth factor |
| 02/19/2004 | US20040033943 Hcn polypeptides and polynucleotides and their use in therapy |
| 02/19/2004 | US20040033941 For suppressing acute chronic rejection responses of a transplant recipient |
| 02/19/2004 | US20040033940 Cyclic hepta-peptide derivative from colonial ascidians, lissoclinum SP |
| 02/19/2004 | US20040033939 Cross-linked glycopeptide-cephalosporin antibiotics |
| 02/19/2004 | US20040033937 Reduction of the electrocardiographic ot interval |
| 02/19/2004 | US20040033936 Reduced or "leuco" forms produced and/or stabilised by mixing the unreduced compounds or the reduced compounds, respectively, with acid and a sulphydryl compound, especially a sulphur-containing amino acid, or peptide or derivative |
| 02/19/2004 | US20040033916 Disinfecting composition |
| 02/19/2004 | US20040033584 Using immunoglobulins to diagnose and treat viral, fungal, bacterial and parasitic infections of the reticuloendothelial system; vetrinary medicine; immunotherapy |
| 02/19/2004 | US20040033583 Isomerases |
| 02/19/2004 | US20040033578 Cloning of a member of the serine-threonine-kinase family |
| 02/19/2004 | US20040033566 Genetically engineered serine protease for diagnosis and treatment of blood disorders |
| 02/19/2004 | US20040033559 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 02/19/2004 | US20040033558 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 02/19/2004 | US20040033548 Compositions and methods for regulating bacterial pathogenesis |
| 02/19/2004 | US20040033538 Administering to the animal an amount of a compound that binds a c-Myc protein effective to treat the disease caused by immunoglobulin E production and/or accumulation |
| 02/19/2004 | US20040033535 Antibodies to OPGL |
| 02/19/2004 | US20040033534 Using peptide mimetics to prevent binding and gene expression activation by phosphorylated aspartyl regulatory protein; decreasing development of antibiotic resistance in pathogenic bacteria; gene expression inhibition |
| 02/19/2004 | US20040033527 Methods of using a three-dimensional model of a Fc epsilon receptor alpha chain |
| 02/19/2004 | US20040033526 Isolated human phospholipase proteins, nucleic acid molecules encoding human phospholipase proteins, and uses thereof |
| 02/19/2004 | US20040033521 Novel core 2 beta-1, 6-N-acetylglycosaminyltransferas E gene |
| 02/19/2004 | US20040033520 Diagnosing metastatic colorectal, stomach and/or esophageal cancer in vitro; immunoassay; radioimaging tumors; immunotherapeutics; genetic vaccines |
| 02/19/2004 | US20040033519 Binary or polynary targeting and uses thereof |
| 02/19/2004 | US20040033517 Compositions and methods relating to endothelial cell signaling using the protease activated receptor (PAR1) |
| 02/19/2004 | US20040033514 Detection of disease related genes |
| 02/19/2004 | US20040033511 Site-specific antibody-mediated activation of proapoptotic cytokines: AMAIZEe (antibody-mediated apoptosis inducing cytokines) |